In 2002, deCODE acquired a Chicago-based medicinal chemistry company in order to discover compounds based on its genetics discoveries and so to begin to develop its own pipeline of new drugs."DeCode to Acquire MediChem Life Sciences in $84M Stock Deal," Genomeweb, 8 January 2002 Over the next few years the company initiated and completed several early-stage clinical trials for potential new treatments for heart attack, peripheral artery disease, and conducted work with partners on asthma and SMA.Company press release, "deCODE genetics, Inc. Provides Product Development Update -- CEP-1347, DG041, DG031, DG051," republished in Biospace, 26 June 2006 These were early examples of what would today be called 'precision medicine' programs: using genetics for target discovery and to select trial participants by testing them for disease susceptibility through the same pathway targeted by the drug.H Hakonsarson et al., "Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction: A Randomized Trial," JAMA, vol 293, issue18, pp 2245–2256 (May 2005)
